BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28716051)

  • 1. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
    Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
    J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
    El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
    J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.
    Villa R; Daidone MG; Motta R; Venturini L; De Marco C; Vannelli A; Kusamura S; Baratti D; Deraco M; Costa A; Reddel RR; Zaffaroni N
    Clin Cancer Res; 2008 Jul; 14(13):4134-40. PubMed ID: 18593991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
    El Bezawy R; Percio S; Ciniselli CM; De Cesare M; Colella G; Dugo M; Veneroni S; Doldi V; Martini S; Baratti D; Kusamura S; Verderio P; Deraco M; Gandellini P; Zaffaroni N; Zuco V
    Cancer Gene Ther; 2022 Oct; 29(10):1394-1404. PubMed ID: 35352023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
    Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
    Singh A; Bhattacharyya N; Srivastava A; Pruett N; Ripley RT; Schrump DS; Hoang CD
    Mol Ther; 2019 Sep; 27(9):1665-1680. PubMed ID: 31227395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal miR-16-5p as a target for malignant mesothelioma.
    Munson PB; Hall EM; Farina NH; Pass HI; Shukla A
    Sci Rep; 2019 Aug; 9(1):11688. PubMed ID: 31406207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
    De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
    J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
    Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-19-5p Enhances Tumorigenesis in Human Colorectal Cancer Cells by Targeting TSPYL5.
    Huang C; Luo H
    DNA Cell Biol; 2018 Jan; 37(1):23-30. PubMed ID: 29240449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
    Busacca S; Germano S; De Cecco L; Rinaldi M; Comoglio F; Favero F; Murer B; Mutti L; Pierotti M; Gaudino G
    Am J Respir Cell Mol Biol; 2010 Mar; 42(3):312-9. PubMed ID: 19502386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
    Grobelny JV; Kulp-McEliece M; Broccoli D
    Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of miR-708 microRNA in telomerase positive and negative human cancer cells.
    Kaul Z; Cheung CTY; Bhargava P; Sari AN; Yu Y; Huifu H; Bid H; Henson JD; Groden J; Reddel RR; Kaul SC; Wadhwa R
    Sci Rep; 2021 Aug; 11(1):17052. PubMed ID: 34426596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
    Xu Y; Zheng M; Merritt RE; Shrager JB; Wakelee HA; Kratzke RA; Hoang CD
    Chest; 2013 Nov; 144(5):1632-1643. PubMed ID: 23828229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.